dx 9065a has been researched along with mocetinostat in 2 studies
| Studies (dx 9065a) | Trials (dx 9065a) | Recent Studies (post-2010) (dx 9065a) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 92 | 7 | 8 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | dx 9065a (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enkhbaatar, P; Murakami, K; Okabe, H; Okabe, K; Okajima, K; Uchiba, M; Yamaguchi, Y | 1 |
| Harada, N; Okajima, K; Uchiba, M | 1 |
2 other study(ies) available for dx 9065a and mocetinostat
| Article | Year |
|---|---|
Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
Topics: Animals; Anticoagulants; Capillary Permeability; Dansyl Compounds; Factor VIIa; Factor Xa Inhibitors; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; In Vitro Techniques; Leukocytes; Lipopolysaccharides; Lipoproteins; Lung; Male; N-Formylmethionine Leucyl-Phenylalanine; Naphthalenes; Neutrophil Activation; Peroxidase; Propionates; Pulmonary Edema; Rats; Rats, Wistar; Recombinant Proteins; Tumor Necrosis Factor-alpha | 2000 |
Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticoagulants; Calcium; Cyclooxygenase 2 Inhibitors; Dalteparin; Edema; Endothelium; Epoprostenol; Fibrin Fibrinogen Degradation Products; Heparin; In Vitro Techniques; Indomethacin; Inflammation; Interleukin-12; Leukocytes; Liver; Liver Diseases; Male; Monocytes; Naphthalenes; Nitrobenzenes; Peroxidase; Propionates; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides; Transaminases; Tumor Necrosis Factor-alpha | 2006 |